Logo

Paired Ends: John Milligan

Jul 23, 2013
Premium

Pacific Biosciences has appointed John Milligan to its board of directors. Milligan is currently President and COO of Gilead Sciences. He has been at Gilead since 1990, and has served a variety of roles, including research scientist and chief financial officer. He holds a BA from Ohio Wesleyan University and a PhD from the University of Illinois.

Filed under

Clinical Sequencing
Sequencing
Next-Generation Sequencing
Pacific Biosciences
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.